RARE CANCERMediastinal TumorWHO 5th Edition Classification

Thymic Carcinoma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A malignant tumour of the thymus gland in the front of the chest. It is biologically more aggressive than thymoma, invades locally and spreads more readily, and - unlike thymoma - is only rarely associated with myasthenia gravis or other autoimmune syndromes.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Superior vena cava obstruction requires urgent assessment
Who It Affects

Adults, median 50-60; slight male predominance

Annual Incidence

Approximately 0.15-0.3 per 100,000 per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Chest pain or a feeling of pressure behind the breastbone
Cough and breathlessness
Facial and arm swelling with distended neck veins (superior vena cava obstruction)
Hoarseness from recurrent laryngeal nerve involvement
Often found incidentally on a chest scan performed for another reason

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

KIT mutations in about 10%CD5 and CD117 positivityGTF2I - characteristic of thymoma rather than carcinoma

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Complete surgical resection where achievable - the strongest predictor of survival

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Postoperative radiotherapy for incomplete resection or advanced stage

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Carboplatin-paclitaxel as standard first-line chemotherapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Sunitinib or lenvatinib in relapsed disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Pembrolizumab in selected patients, with careful autoimmune toxicity monitoring

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Worse than thymoma. Five-year survival is roughly 30-50% overall, but considerably better for completely resected early-stage disease. Masaoka-Koga stage and completeness of resection are the dominant prognostic factors.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

KIT-mutated cases may respond to imatinib or sunitinib; combination immunotherapy and antiangiogenic strategies are in trials, coordinated internationally through thymic malignancy interest groups.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Thymic Carcinoma

Browse All Oncologists

Dr. Giuseppe Giaccone

Medical Oncologist

30+ yrs exp

Georgetown University (formerly NCI)

Washington, DC, USA

Medical OncologyThymic MalignanciesGlobal Trials
Vetted DirectoryConsult Specialist

Dr. Toh Han Chong

Medical Oncologist

25+ yrs exp

NCCS

Singapore, Singapore

Medical OncologyThymic CarcinomaTargeted Agents
Vetted DirectoryConsult Specialist

Prof. Luciano Mariani

Thoracic Surgeon

20+ yrs exp

Regina Elena Institute

Rome, Italy

Thoracic SurgeryThymic CarcinomaExtensive Resections
Vetted DirectoryConsult Specialist

Dr. Raja Sundaram

Surgical Oncologist

30+ yrs exp

Apollo Hospitals

Chennai, India

Surgical OncologyThymic Tumor ResectionThymoma Teams
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Thymic Carcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult